Tvardi therapeutics, inc.TVRD.US Overview

US StockHealthcare

(No presentation for TVRD)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

TVRD Overall Performance

TVRD AI Analysis & Strategy

TVRD Recent Performance

-3.36%

Tvardi therapeutics, inc.

0.81%

Avg of Sector

-1.14%

S&P500

TVRD PowerScanner

TVRD Key Information

TVRD Valuation Metrics

TVRD Earnings Table

TVRD Profile

Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).